Specialties – Page 133

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY 08/01/2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Clinical Updates news Oncology Specialties

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

news Oncology Specialties

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.

Clinical Updates news Oncology Specialties

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY 07/31/2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Infectious Diseases Specialties

Mass Ivermectin Administration for Malaria Control: Translational Insights from Recent Cluster-Randomized Trials

By MedXY 07/31/2025

Recent cluster-randomized trials in Kenya and Burkina Faso provide mixed but informative evidence on the efficacy and safety of mass ivermectin administration for malaria control, highlighting both its potential and limitations.

Cardiology Clinical Updates news Specialties

Acute Normovolemic Hemodilution in Cardiac Surgery: No Reduction in Allogeneic Transfusion—Insights from a Multinational Randomized Trial

By MedXY 07/31/2025

A large multinational trial found that acute normovolemic hemodilution (ANH) did not significantly reduce allogeneic red-cell transfusion in adult cardiac surgery patients, with similar safety outcomes compared to usual care.

Clinical Updates Hematology-Oncology Medical News Specialties

Mitochondrial Donation and Preimplantation Genetic Testing: Innovations in Reducing mtDNA Disease Transmission

By MedXY 07/31/2025

Mitochondrial donation by pronuclear transfer and preimplantation genetic testing effectively reduce transmission of pathogenic mtDNA variants, offering hope for families at risk of mitochondrial diseases.

Clinical Updates Hematology-Oncology Medical News Specialties

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial

By MedXY 07/31/2025

MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.

Clinical Updates Diabetes & Endocrinology news Specialties

FDA Approves Once-Weekly Skytrofa (Lonapegsomatropin-tcgd) for Adult Growth Hormone Deficiency: Clinical Implications and Evidence Review

By MedXY 07/31/2025

Skytrofa, a once-weekly injectable growth hormone, is FDA-approved for adult GHD, offering improved adherence and positive metabolic outcomes. Clinical trials show superior efficacy and favorable safety compared to daily somatropin.

Clinical Updates news Oncology Specialties

Dupilumab as a Steroid-Sparing Strategy for ADC-Induced Skin Toxicities: Enhancing Cancer Therapy Continuity

By MedXY 07/31/2025

Dupilumab controls ADC-related skin toxicities more effectively than systemic steroids, reducing cancer treatment discontinuation and improving response rates.

Clinical Updates Hematology-Oncology news Specialties

Ivosidenib Plus Azacitidine Significantly Improves Survival in IDH1-Mutated AML: Long-Term Results from the AGILE Study

By MedXY 07/31/2025

The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.

news Oncology Specialties

Limited Direct Comparison of Me-Too Oncology Drugs with First-in-Class Agents: Clinical Implications and Regulatory Considerations

By MedXY 07/31/2025

Analysis of FDA approvals from 2009–2020 reveals only 29% of next-in-class oncology drugs underwent head-to-head RCTs against originals, with just 22% showing survival benefits, highlighting a need for incentivized comparative trials.

Neurology news Specialties

Sex-Specific Brain Volume Loss After Traumatic Brain Injury: Greater Impact in Older Women

By MedXY 07/31/2025

A study from the Framingham Heart Study cohort reveals that traumatic brain injury (TBI) is linked to significant brain volume loss in older women but not men, highlighting sex-specific vulnerability to neurodegeneration post-TBI.

Cardiology Clinical Updates news Public Health Specialties

High-Dose and Adjuvanted Flu Vaccines Offer Equivalent Protection for Older US Adults

By MedXY 07/31/2025

A large US study finds adjuvanted and high-dose quadrivalent influenza vaccines provide comparable protection against lab-confirmed flu in seniors, supporting current immunization guidelines.

$FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease$

Clinical Updates news Rheumatology Specialties

FDA Approves First Vagus Nerve Stimulation Device for Rheumatoid Arthritis: New Horizons for Refractory Disease

By MedXY 07/31/2025

The FDA has approved the first vagus nerve stimulation device for moderate-to-severe rheumatoid arthritis unresponsive to biologic or synthetic DMARDs, offering a novel neuromodulatory approach to disease management.

Cardiology Clinical Updates news Specialties

Balancing Stroke Prevention and Bleeding Risk: Timing of DOAC Restart After Serious Bleeding in Atrial Fibrillation

By MedXY 07/31/2025

Early resumption of DOACs after serious bleeding in AF patients may lower stroke risk but significantly increases recurrent bleeding. Individualized decision-making and further research are recommended.

Diabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY 07/31/2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.

HIV/AIDS Medical News news Public Health Specialties

FDA Approves Lenacapavir: A Twice-Yearly Injectable PrEP Transforming HIV Prevention

By MedXY 07/31/2025

Lenacapavir (Yeztugo) becomes the first FDA-approved, twice-yearly injectable PrEP, offering robust long-acting HIV prevention and addressing key adherence barriers.

Clinical Updates Infectious Diseases news Specialties

Fecal Microbiota Transplantation versus Vancomycin in Primary Clostridioides difficile Infection: A Noninferiority Randomized Trial

By MedXY 07/31/2025

FMT is noninferior to vancomycin for primary CDI, with similar cure rates and safety, suggesting it may be a viable first-line therapy.

Medical News news Orthopedics Specialties

Walking More Than 100 Minutes Daily May Lower Risk of Chronic Low Back Pain

By MedXY 07/31/2025

A large prospective cohort study links daily walking of over 100 minutes to reduced risk of chronic low back pain, emphasizing walking volume over intensity as a preventive strategy.